Evren Technologies, Inc
Advancing PTSD Treatment with an FDA Breakthrough Device
Gainesville, FL
Biotechnology
Health Tech
Evren Technologies is developing a discrete earbud that utilizes a groundbreaking treatment for PTSD to help people easily manage their symptoms and improve outcomes. Backed by clinical evidence, the Phoenix® improves patient health and well-being with fewer side effects and higher patient engagement than seen with current prescription drugs and therapies.*
$184,093
raised
75
Investors
$15.1M
Valuation
$6.65
Price per Share
$399.00
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
Reg CF
Offering
Rewards
Get rewarded for investing more into Evren Technologies, Inc:
$399+
Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$1,000+
Investment
Investor | $1,000+
Invest $1,000+ and receive 50% off device purchase (coupon for use once the product is available on the market).
$5,000+
Investment
Watt | $5,000+
Invest $5,000+ and receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).
$10,000+
Investment
Franklin | $10,000+
Invest $10,000+ and receive 10% bonus shares + 50% off 2 device purchases (coupons for use once the product is available on the market).
$25,000+
Investment
Edison | $25,000+
Invest $25,000+ and receive 20% bonus shares + 50% off 3 device purchases (coupons for use once the product is available on the market).
$50,000+
Investment
Tesla | $50,000+
Invest $50,000+ and receive 25% bonus shares + 50% off 4 device purchases (coupons for use once the product is available on the market).
Reasons to Invest
FDA Breakthrough Device Designation | Evren’s device, the Phoenix®, was recently awarded Breakthrough Device Designation by the FDA, demonstrating that it could provide better treatment than the current standard of care in the serious, life-threatening condition of PTSD. Evren is also the recipient of a SBIR from the National Institute of Mental Health (NIMH) and a contract from the Army Medical Research and Development Command
Novel Technology for a Massive Growing Market | PTSD is an underserved, $22.5 Billion-dollar market with 66% of those suffering currently seeking new treatment solutions. 15 Million Americans will suffer from PTSD in any given year and over 60 million had PTSD during the height of the COVID shutdown.**
High User Satisfaction and Low Dropout Rates | 100% of Phoenix® users wanted to continue using the device after the pilot trial and all of them were willing to pay out-of-pocket for it.
Evren Technologies currently has a working prototype of the Phoenix® earbud and a beta version of the accompanying app
*Information based on internal research with resources provided by the National Center for PTSD ( source)
A Groundbreaking Treatment for PTSD
PTSD affects millions of Americans, but current treatments simply aren’t working. Sixty-six percent of those suffering from PTSD—which includes 20% of veterans, first responders, and front-line nurses, and 6% of the overall population—are actively seeking out new solutions (source, source, source). Unfortunately, the medical system still relies primarily on antidepressants and therapy, which offer unreliable treatment, are often accompanied by serious side effects including increased suicidality, and can even worsen symptoms. As a result, dropout rates are high and improvement rates are low.
This is why we’re creating the Phoenix, an innovative earbud device that is capable of integrating smoothly into a user’s lifestyle, providing on-the-go treatment that empowers patients to control their own PTSD. The Phoenix will provide personalized levels of vagal nerve stimulation to reduce PTSD symptom severity and improve quality of life without the harmful side effects seen with prescription drugs.
The stimulation provided through our patented closed-loop algorithm will offers a huge improvement over current treatments, with clinical results that garnered an FDA Breakthrough Device Designation. To date, 100% of users wanted to continue usage past the end of the trial, 100% were willing to pay out-of-pocket for the device, and the vast majority of users would recommend the device to a friend (95.6 Net Promoter Score).
*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.
The device reduces PTSD severity, which includes symptoms such as depression, anxiety, insomnia, nightmares & flashbacks, social avoidance, and suicidality — and does so with no significant side effects. The Phoenix was recently awarded Breakthrough Device Designation by the FDA based on early clinical data, and we’re now ready to launch it into the next phase of development as we look to serve those chronically suffering from PTSD.
The Problem
New treatments are needed to address the challenges of PTSD
According to the National Center for PTSD, about 15 million adults in the US suffer from PTSD during a typical year, and the pandemic has been far from typical. Rates among veterans, EMTs, nurses, police, and firefighters are the highest, at around 20%, though an overall 6% of the American population will have PTSD at some point in their lives. (source)
While traditionally associated with veterans, PTSD can affect anyone who has experienced trauma, and significantly increases the likeliness of suicide (13x more likely from those suffering from PTSD; source). The prevalence of domestic violence and sexual abuse also contribute to higher rates of PTSD among women versus men (8% vs. 4%). PTSD also comes with multiple serious comorbidities, including depression and substance abuse. (source)
(source)
Despite millions of Americans dealing with PTSD on a daily basis, far too many patients are still looking for relief. The primary treatment option is antidepressants, which can cause increased suicidality and are intended only for short-term use.
(source)
Therapy, another common treatment in the patient roadmap, is more time and resource-intensive than many people can afford, and still lacks proper research, phenotyping, and individualization—oftentimes worsening symptoms. Researchers and academics agree that current therapies are inadequate, indicating a pressing need for new approaches to the issue.
The Solution
Evren's Phoenix earbud will put the power of treatment in the hands of the user
Evren’s Phoenix earbud will treat PTSD by stimulating the vagus nerve with a light electrical tingle, providing personalized dosing based on users’ stress levels. Vagal nerve stimulation is directly related to the balance of calm and stress in the body and influences how we store and retrieve fearful memories.
If you are interested in more information about the science behind the Phoenix vagal nerve stimulation, visit Evren’s website. (www.RiseAbovePTSD.com)
By putting the power of treatment in the hands of the user, the Phoenix earbud will provide an option for discreet treatment that can be used for both managing daily symptoms and navigating high-stress situations. The results of our clinical pilot trial showed a reduction in PTSD symptom severity (measured through CAPS-5), improved quality of life (PROMIS-29), and no significant side effects. Additionally, the earbud will pair with a free app, where patients can track symptoms, record sleep activity, and identify triggers.
*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.
We plan to sell our Phoenix device via three channels: A direct-to-consumer (DTC) digital ad campaign for early movers, sales to the Department of Veterans Affairs, and finally reimbursed sales through healthcare providers. Our current DTC model will begin at $99/mo for the first year (until the earbud is paid off - Rx required), then continuing at $49/mo to cover additional supplies and support.
In addition to product sales, we plan to leverage our growing database of de-identified data, which can be used to support advancements in the understanding and treatment of PTSD, while also making us a potential acquisition target for health management companies. Please note there is no guarantee on future results. Refer to our Offering Materials and Risk Factors for more information regarding our offering.
*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.
Evren has developed a connected ecosystem to support, treat, and connect patients with clinicians
Evren is not only offering a device for the treatment of PTSD, but an entire platform to support, treat, and connect patients with clinicians. As an organization, we are highly focused on the needs of the patient. As part of our initial ethnographic research with patients and clinicians, we discovered that one of the first things patients’ are asked to do is to start tracking their symptoms to establish a baseline and allow them to track progress. Unfortunately there was no app on the market to specifically help users with PTSD actively track their symptoms day-by-day. Since then, the Phoenix PTSD App has evolved to offer further functionality to support patients and clinicians.
With an earbud that collects biosignals for our closed-loop algorithm, and an app collecting patient symptoms, we can do two major things:
- Create a portal where clinicians, once given permission by their patient, can track patient’s progress and use insights to develop better therapy plans.
- Create a HIPAA-compliant database of de-identified data (data with no personal information that could be used to identify an individual) to learn about PTSD and help develop better solutions for the future.
The Market
Failing to effectively treat millions of Americans means an unmet need and massive market
PTSD is an enormous global market, valued at $22.5B in the US alone.* In the US, there are approximately 15M cases of PTSD each year, with 66% of people affected by PTSD still looking for treatment solutions. PTSD affects a wide-ranging demographic,and the number of those affected has spiked dramatically during the ongoing COVID pandemic to over 60 Million Americans.
*Information based on internal research done by Evren Technologies
*Information based on internal research done by Evren Technologies
(source)
Based on our knowledge, no existing wearable stimulation device has received FDA approval for the treatment of PTSD, and not one includes Evren’s patented closed-loop stimulation. Other wearable neuromodulation devices created for use as a PTSD treatment rely on old technology and/or poor design, resulting in underwhelming results. Evren’s Phoenix device leverages improvements on existing technologies, refining the user experience and outcomes.
Antidepressants, a more common treatment option, are intended only for short-term use, while therapy can make symptoms worse, especially if a patient is unable to complete their full treatment. Other PTSD treatments, such as psychedelics, are still actively being explored and have yet to be cleared.
Additionally, these treatments are only proving effective when paired with exposure therapy, meaning patients unwilling to go through therapy will not be able to use and benefit from these solutions. Compared to these existing and developing standards of care, the Phoenix device has much lower side effects, higher response rates, and a lower dropout percentage.
Our Traction
FDA designation, NIMH funding, and excellent user feedback
Since Evren started in 2019, we’ve made incredible strides and have seen a phenomenal response from our initial users, including the completion of multiple iterations of our prototype as well as a clinical trial during the COVID-19 shutdown. Most significantly, we received Breakthrough Device Designation from the FDA based on our pilot trial results, indicating confidence that we may provide better treatment than the current standard of care in the serious, life threatening and chronic condition of PTSD.
We now have a working device and clinical evidence, and are nearly ready to launch the Phoenix® PTSD App. Our app allows users to document their symptoms on the go and helps them try to identify individualized triggers, functionality not provided by the VA’s PTSD Coach apps, the current market leader. Our next step is to launch the industrial design phase, enabling production of the fully miniaturized earbud, and from there, a pivotal trial for official FDA clearance.
*The above is a rendering of Evren's Phoenix app. Images feature a computer generated wireframe. Product is still currently under development.
The Phoenix has received a 95.6 Net Promoter Score, with 100% of users wanting to continue use past the end of their trial and 100% of users willing to pay a monthly out-of-pocket fee. Patients have truly connected with their Phoenix device experience. Here are some quotes from pilot trial participants:
*Testimonials may not be representative of the experience of other customers and are not a guarantee of future performance or success.
Evren has received $232,285 in PPP awards and EIDL loans. In addition, we accumulated $1.571M comprising $814,900 in two series of convertible notes, $140,000 in promissory notes issued to an officer, $10,000 in prize money for a video contest, and $256,000 in an NIH grant.
Why Invest
Working towards a better future for those suffering from PTSD
We envision a better future for those suffering from PTSD—though it doesn’t stop there. Our Phoenix earbud is an extremely scalable technology, with vagal nerve stimulation approved for the treatment of many other disorders, including epilepsy, opioid withdrawal, major depressive disorder, and migraines, with potential application for a longer list that includes anxiety, insomnia, and traumatic brain injury.
*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.
Join us on our mission to improve countless lives, enable a happier, healthier future, and empower patients to #RiseAbovePTSD.
*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.
Offering Summary
Company | : | Evren Technologies, Inc |
Corporate Address | : | 404 SW 140th Terrace, Suite 50, Gainesville, FL 32669 |
Offering Minimum | : | $9,994.95 |
Offering Maximum | : | $1,069,998.30 |
Minimum Investment Amount(per investor) | : | $399.00 |
Terms
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 1,503 |
Maximum Number of Shares Offered | : | 160,902 |
Price per Share | : | $6.65 |
Pre-Money Valuation | : | $15,085,870.80 |
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives and Bonuses*
Time-Based
Friends and Family Early Birds
Invest within the first 72 hours and receive 15% bonus shares.
Early Bird Bonus
Invest within the first week (7 calendar days) and receive 10% bonus shares.
Amount-Based
Investor | $1,000+
Invest $1,000+ and receive 50% off device purchase (coupon for use once the product is available on the market).
Watt | $5,000+
Invest $5,000+ and receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).
Franklin | $10,000+
Invest $10,000+ and receive 10% bonus shares + 50% off 2 device purchases (coupons for use once the product is available on the market).
Edison | $25,000+
Invest $25,000+ and receive 20% bonus shares + 50% off 3 device purchases (coupons for use once the product is available on the market).
Tesla | $50,000+
Invest $50,000+ and receive 25% bonus shares + 50% off 4 device purchases (coupons for use once the product is available on the market).
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Evren Technologies, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $6.65 / share, you will receive 110 shares Common Stock, meaning you'll own 110 shares for $665. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Insider Investment Notice
Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.
Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$202,707.00
USD
$116,875.00
USD
Cash And Cash Equivalents
$64,269.00
USD
$13,388.00
USD
Accounts Receivable
$0.00
USD
$0.00
USD
Short Term Debt
$436,215.00
USD
$514,900.00
USD
Long Term Debt
$150,000.00
USD
$150,000.00
USD
Revenues And Sales
$0.00
USD
$0.00
USD
Costs Of Goods Sold
$0.00
USD
$0.00
USD
Taxes Paid
$0.00
USD
$0.00
USD
Net Income
$14,956.00
USD
-$418,616.00
USD
Risks
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Updates
Evren Technologies is Offering Bonus Shares!
17 days ago
Evren Technologies Community,
Ready to invest into Evren Technologies, Inc.?
We’ve designed a number of perks where you receive extra capital based on your investment amount - buy more shares, get more shares!
Here’s the list of perks that you can also find on our StartEngine raise page:
$399+ Investment - This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section on our raise page.
$1,000+ Investment (Investor) - Receive 50% off device purchase (coupon for use once the product is available on the market).
$5,000+ Investment (Watt) - Receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).
$10,000+ Investment (Franklin) - Receive 10% bonus shares + 50% off 2 device purchases (coupon for use once the product is available on the market).
$25,000+ Investment (Edison) - Receive 20% bonus shares + 50% off 3 device purchases (coupon for use once the product is available on the market).
$50,000+ Investment (Tesla) - Receive 25% bonus shares + 50% off 4 device purchases (coupon for use once the product is available on the market).
What are you waiting for? Head over to our raise page and take advantage of this opportunity while time permits!
Our executive team would like to thank you in advance for your support.
Warmly,
Weaver Gaines
Notice of Material Change in Offering
23 days ago[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the Evren Technologies, Inc offering. Here's an excerpt describing the specifics of the change:
Campaign is extending by 60 days and updating 2020/2021 financials
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
Tomorrow! Live Q&A Webinar With Dr. Richard Marshall.
24 days ago
Hello Evren Community! 👋
Join us tomorrow for our live investor Q&A webinar with Dr. Richard Marshall at 12:00 PM PST/3:00 PM EST!
This is your last chance to register before we go live.
Our discussion will be focused on trauma, PTSD and VNS. We hope to see you there! You can register for the webinar here.
We encourage everyone to spread the word to their network about investing and joining this exclusive online event!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Live Q&A Webinar With Dr. Richard Marshall!
26 days ago
Hello Evren Community!
Join Evren Technologies and Dr. Richard Marshall for a live investor Q&A webinar April 29th at 12:00 PM PST/3:00 PM EST.
There are only 3 days left to register! Register for our live event while you still can.
Our discussion will be focused on trauma, PTSD and VNS. We hope to see you there! You can register for the webinar here.
We encourage everyone to spread the word to their network about investing and joining this exclusive online event!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Live Q&A Webinar With Dr. Richard Marshall!
27 days ago
Hello Evren Community!
Join Evren Technologies and Dr. Richard Marshall for a live investor Q&A webinar April 29th at 12:00 PM PST/3:00 PM EST.
There are less than 5 days left to register!
Our discussion will be focused on trauma, PTSD and VNS. We hope to see you there! You can register for the webinar here.
We encourage everyone to spread the word to their network about investing and joining this exclusive online event!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Evren Technologies Awarded $172K Military Contract.
28 days ago
Evren Technologies Community,
Evren is thrilled to be partnered with Emory University and Dr. Doug Bremner, a leading PTSD researcher and an authority on acute stress, for this contract from the Army Medical Research and Development Command. This work presents an opportunity for significant improvements to managing stress response in both military and civilian applications.
In 2018, 28% of all medical evacuations were attributed to mental-health related symptoms. It is expected that Acute Stress Reactions (ASRs) will occur with increased frequency in far forward combat environments in future conflicts. Those who experience an ASR are at far greater risk of developing Post-Traumatic Stress Disorder (PTSD).
ASRs are also common among first responders. It is estimated that police officers experience 7 traumas per year on average, and firefighters experience an average of 9 significant traumas in the first three years of service.
There are currently no FDA-approved treatments for ASRs. Existing treatments for PTSD, including psychotherapy and medications, have limited efficacy in many cases, and in others are ineffective.
taVNS Reduces Stress Responses
Acute Stress Reactions (ASRs) are a normal human response to stressful or life-threatening situations. Unfortunately, ASRs can negatively impact cognitive, physiological and emotional functioning. They have also been connected to poor decision making and diminished task performance. Therefore, it is critical that we identify ways to reduce stress responses in order to maintain soldier performance in high threat environments.
Transcutaneous auricular vagal nerve stimulation (taVNS) is a non-invasive, painless treatment that can be self-administered using a small device designed to fit inside the ear and gently stimulate the vagus nerve. Preliminary research suggests that taVNS is associated with reduced stress reactivity.
The goals of this project are:
Goal 1: Demonstrate the effectiveness of the Phoenix® research device (CR-100) in maintaining performance after trauma or during extreme stress.
Goal 2: Improve device durability for use in hazardous or extreme environments and evaluate usability improvements.
Goal 3: Develop relationships with Army and DoD personnel interested in utilizing the system and jointly develop requirements for the device and clinical trial.
Anticipated Benefits and Potential Commercial Applications
taVNS has demonstrated great efficacy in treating PTSD in clinical trials, resulting in the Evren Phoenix device having been granted the FDA’s “Breakthrough Device” designation.
This technology has demonstrated the capability to reduce sympathetic response, reduce cortisol release, improve memory encoding capability, and decrease inflammation markers. This suggests that even after soldiers suffer significant emotional traumas, it could significantly mitigate acute stress response and improve functioning in far forward combat environments.
We intend to provide military field hospitals with an all-inclusive, multi-unit kit. We also plan to supply far forward battlefield medics with a small, single device pouch.
Civilian Market
Emergency responders commonly experience flashbacks of traumatic events. These flashbacks are referred to as "acute stress responses" (ASRs) and can occur among all types of emergency responders, including police, firefighters, and Emergency Medical Services (EMS). Beyond day to day experience, disasters can also cause acute stress reactions in both first responders and survivors.
ASRs create a substantial burden on first responders and limit the availability of the public services provided to the communities they serve. Without proper care, ASRs can lead to PTSD.
A portable and rugged Acute Stress Reaction device would address a significant market opportunity in the disaster relief and response industries.
Join Evren Technologies as an Early Investor
We need your support in the development and distribution of the Phoenix®️ device. Invest in Evren Technologies on StartEngine and support a post-traumatic stress disorder treatment for millions of PTSD sufferers.
Warmly,
Weaver Gaines
Live Q&A Webinar With Dr. Richard Marshall!
29 days ago
Hello Evren Community!
Join Evren Technologies and Dr. Richard Marshall for a live investor Q&A webinar April 29th at 12:00 PM PST/3:00 PM EST.
There’s only a week left to register!
Our discussion will be focused on trauma, PTSD and VNS. We hope to see you there! You can register for the webinar here.
We encourage everyone to spread the word to their network about investing and joining this exclusive online event.
Warmly,
Weaver Gaines
CEO
Evren Technologies
Meet the Visionaries Tackling Post-Traumatic Stress Disorder.
about 1 month ago
Evren Technologies Community,
Current treatments for PTSD include psychotherapy and pharmaceuticals; however, neither are consistently effective.
About two-thirds of people treated with talk therapy do not see their symptoms improve, while a large percentage may experience worsening symptoms.
Evren is focused on providing the best possible care for patients living with PTSD, and our team has extensive experience in research and development of biomedical devices, consulting, entrepreneurship, and medical technology.
In today's investor article, I want to take a moment to introduce you to the leaders who will be making a drug-free solution to PTSD widely available to the millions of sufferers in America who are still seeking treatment.
Weaver Gaines, Chairman and CEO
Weaver Gaines has over 40 years of entrepreneurial, management, and legal experience, including over 25 years as a founder, fund-raiser, and manager of start-up life science companies. Most recently, he was a co-founder and CEO of OBMedical Company, a medical device company that developed and received FDA clearance for an electronic maternal fetal monitor, which was acquired by Philips Healthcare in 2018.
Gaines received a BA from Dartmouth College and a JD from the University of Virginia School of Law and was an Infantry officer who served in Vietnam from 1969-70, with a final rank of Captain.
Neil Euliano, Chief Technology Officer
Neil Euliano has spent the past 20 years leading teams developing medical devices and technology. He is the chief designer and manager of the FDA cleared Philips Healthcare VentAssist team that developed intelligent decision support software for ventilated patients. He holds over 40 US patents and has ten more pending. In addition, he has a long history in managing multidisciplinary medical development teams and 19 years of experience managing R&D grants, including over $12M in industry and government funded research. His commercialization and entrepreneurial experience includes being the cofounder of two companies, both of which led to FDA clearance, commercial sales, and acquisition. He has been involved in the successful FDA clearance of more than 6 medical devices.
Euliano holds a PhD in Signal Processing and Electrical Engineering, an MSEE in Electrical Engineering, and a BSE in Computer Science all from the University of Florida.
Kimberly A. Ramsey, Chief Financial Officer
A serial entrepreneur, with 30 years progressive corporate finance and operations experience Ramsey has played a key role in raising over $100 million, including several successful IPOs. Most recently, she has been providing executive consulting services to medical device start-ups as founder and president of Bio/Med CXO. As co-founder and Chief Financial Officer for OBMedical Company, she played a key role in forwarding a ground-breaking wireless fetal/maternal monitor for use in labor and delivery departments, raising over $10M in private equity, leading to a successful acquisition by Philips Healthcare. Prior to that, she was key to successful mergers and IPOs in the biotech, med device and high-tech arenas. Ramsey holds a BSAc from the Fisher School of Accounting at the University of Florida.
Stephanie Warrington, Member of Board of Directors
Ms. Warrington has been an independent consultant since 2014, advising a wide range of early stage medtech and biotech companies in strategic and business planning, investor relations, licensing, product development and building early stage corporate infrastructure. She has over 25 years of experience in the healthcare industry, with the past 15 years being involved in cutting edge startups working to solve difficult healthcare challenges. She was a founder, president and director of TrueMotion Spine, Inc., a Co-founder and VP, Corporate Development for Xhale, Inc., and President of Synogen, Inc. She holds an MBA, an MHA, and a BS in Business Administration from the University of Florida.
Robert V. House, Member of Board of Directors
Dr. House is an independent consultant and was previously Senior Vice President, Government Contracts of Ology Bioservices, with over 20 years' experience leading the contract management and oversight process of major US Government contracts with various agencies including the DoD, NIH, HHS, and other federal entities. He is also a director of Arrevus, Inc. He has more than 76 peer reviewed publications, plus numerous review articles, book chapters, and books. In addition, he is an adjunct professor at George Mason University. Dr. House is a graduate of the University of North Carolina at Chapel Hill, where he received his BA (Zoology), his MS in Public Health, and his PhD (Medical Parasitology). He will play a major role in our non-dilutive financing initiative.
Richard Ferrari, Member of Board of Directors
Mr. Ferrari is a Co-Founder of De Novo Ventures which has $650 million under management and which is one of the premier firms dedicated to Medical Devices and Biotechnology. He has raised over a billion dollars for companies he has directly influenced and participated in approximately 1.5 billion dollars in acquisition events.
Additionally, he has been a successful CEO of two publicly traded medical technology companies. Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters which was eventually acquired for $125 million by Boston Scientific. His most recent success, CardioThoracic Systems (CTS), the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was acquired by Guidant for $350 million in November 1999. Mr. Ferrari was a co-founder of CTS and the force that led the company to an initial public offering in only 7 months, the fastest of any medical technology company in history. Additionally, Rich was the co-founder of the MTG Group which developed Ensure femoral closure device which sold to J&J for $100 Mill returning 10x to investors and IVS which developed the Star Close and sold to Abbott for $100Mill also returning 10x to investors. He is also the co-founder of Transaortic, an integrated femoral sheath and embolic capture system for TAVR procedure which sold last year to Medtronic. He was also the Executive Chairman of SentreHeart where he led the acquisition to Atricure for $300Mill.
Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. He holds a BS degree from Ashland University and an MBA from the University of South Florida.
Suha Jhaveri, Member of Board of Directors
Ms. Jhaveri is presently the Chief Commercial Officer and Head of Business Development of Leyden Labs. Previously she was VP, Market Development of Vir Biotechnology, Global Commercial Leader and New Product Planning for Ultragenyx Pharmaceuticals. Prior to that, she was the Chief Operating Officer of OBMedical Company, and held a variety of executive positions with biotech and tech companies as well as working as a consultant for Boston Consulting Group. She holds an MBA from Harvard, a MA in Economic Development from the University of Sussex, and a BA in International Relations from Stanford University.
Invest in Evren and Create a Positive Social Impact
Our team envisions a future in which those suffering from Post-Traumatic Stress Disorder can be treated effectively.
We invite you to participate in our equity crowdfunding campaign. Please visit our raise page, where you can learn more about our mission to improve countless lives and bring a happier, healthier future to those in need.
Warmly,
Weaver Gaines
Live Q&A Webinar With Dr. Richard Marshall!
about 1 month ago
Hello Evren Community!
Join Evren Technologies and Dr. Richard Marshall for a live investor Q&A webinar April 29th at 12:30 PM PST/3:30 PM EST.
Our discussion will be focused on trauma, PTSD and VNS.There are two weeks before we go live so register now while you still have the chance!
We hope to see you there! You can register for the webinar here.
We encourage everyone to spread the word to their network about investing and joining this exclusive online event!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Our Community Joins In! | Insider Investment Notice
about 1 month agoWe’re excited to see our community come in and invest in Evren Technologies!
Our insiders have invested a total of $18,005.31 into this offering.
We hope you join us on our mission to create a better treatment for PTSD. Invest in Evren today!
Please refer to the Company’s offering materials for further information and refer to the Company’s Risk Factors.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}